After additional adjustments for potential confounding tumor characteristics, such as tumor size and hormone receptor status, the relationship between the follow-up levels of homocysteine and the ability of treatment arms to achieve a pCR in patients remained significant (adjusted ORfollow-up homocysteine × arm = 47.58, 95%CI: 1.60–1411.93, p=0.026; Table 3). The gene discussed is NR4A1; the disease is neoplasm.